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Development of hepatocellular carcinoma (HCC) is associated with alterations in the 
TGF-β signaling pathway, which regulates liver inflammation and can have tumor 
suppressor as well as promoter activities. Little is known about the roles of specific 
members of this pathway at specific of HCC development. We performed transcriptome 
analyses for 488 human HCCs that include TCGA data to identify and validate the 
effects of this pathway in HCC and identify potential therapeutic targets. Our data 
reveals that decreased levels of TGF-β–related genes, associated with loss of TGF-β 
tumor suppressor function and a significantly poorer survival as compared to the group 
with increased levels of TGF-β related genes (P=.0129). About 38% of HCC samples 
showed somatic mutations in at least one of the TGF-β members. These alterations 
correlate with DNA repair genes such as FancD2 but irrespective of known risk factors 
such as HBV, HCV and alcohol. SPTBN1, a Smad3 adaptor, was mutated in the largest 
proportion of samples (12/202, 6%). Further functional validation identified a loss of 
function mutation of SPTBN1-D1089Y, which leads to decreased FancD2 levels and 
increased sensitivity to DNA crosslinking agents. Interestingly, we also observed strong 
correlations between the inactivated TGF-β signature and deregulation of Sirtuin 
pathways. Additional analysis of Sirtuins in TGF-β deficient cells revealed positive 
feedback regulation of Sirtuins by TGF-β.  Loss of TGF-β signaling inhibits Sirt1 and 
Sirt6 expression and vice versa.  Overall, our findings provide new insight into how 
disruption of the TGF-β pathway correlates with deregulation of DNA repair pathway 
and Sirtuins, which lead to increased genomic instability, epigenetic changes and 
thereby promotes liver cancer progression. 
